Amager Hospital, Denmark has entered an agreement with ViroGates for the use of suPARnostic® TurbiLatex in clinical routine practice for the triage and severity assessment of all acute clinical patients in the Emergency Room.

The hospital is run by the Capital Region and treats approximately 50,000 patients annually of which approximately 16,000 are admitted for hospitalisation.

Professor, Dm.Sc, MD, Ove Andersen comments:
“Over the last years, suPAR has shown to be a strong marker of risk in acute medical patients independent of the clinical signs used to triage patients. The addition of suPAR improves risk prediction of both low- and high-risk acute medical patients and suPAR can therefore corroborate the decision of admission or discharge.
We are pleased that Amager Hospital will now have access to the knowledge provided by suPAR."

CEO Jakob Knudsen, says in a comment:
”We are very pleased to announce another clinical customer that starts using suPARnostic® to help in the risk assessment of acute clinical patients. We are furthermore happy to see that Amager Hospital will be the first customer to run the newly developed suPARnostic® TurbiLatex product at its clinical biochemistry laboratory on the Roche Diagnostics cobas instrument.
We look forward to work with other hospitals to curb the effects of the increasing number of patients with co-morbidities that are so difficult to risk assess. With the availability of suPARnostic®, risk assessment will be improved, allowing better clinical decisions, better patient care and optimisation of hospital resources.”